MBX Biosciences (MBX) Change in Accured Expenses (2023 - 2026)

MBX Biosciences (MBX) has 4 years of Change in Accured Expenses data on file, last reported at -$4.9 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 970.43% year-over-year to -$4.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (down 66.64% YoY), and the FY2025 full-year result was $6.8 million, up 114.32% from the prior year.
• Change in Accured Expenses eased to -$4.9 million in Q1 2026, from $4.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $4.5 million in Q4 2025 to a low of -$4.9 million in Q1 2026.
• A 4-year average of $392900.0 and a median of $177500.0 in 2024 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses surged 2293.6% in 2025 and sank 970.43% in 2026, its largest moves.
• Tracing MBX's Change in Accured Expenses over 4 years: stood at -$1.2 million in 2023, then surged by 82.81% to -$203000.0 in 2024, then surged by 2293.6% to $4.5 million in 2025, then slumped by 209.07% to -$4.9 million in 2026.
• Business Quant data shows MBX's Change in Accured Expenses at -$4.9 million in Q1 2026, $4.5 million in Q4 2025, and $2.0 million in Q3 2025.